# Junta clínica — PT-pseudo_afbc5ebc0d4e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_afbc5ebc0d4e",
  "pid": "PT-pseudo_afbc5ebc0d4e",
  "task": 1,
  "psa": 19.0,
  "age": 73,
  "months": 3,
  "pirads": "4",
  "psad": 0.29,
  "psav": 4.32,
  "psap": 14.6,
  "vol": 65.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.7148355,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis",
  "meds": "simvastatin, rosuvastatin, paracetamol PRN",
  "notes": "PSA 19 ng/mL. PI-RADS 4. PSAD 0.29. Prostate volume 65 mL. DRE nodus. csPCa 0.71.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "181 cm",
    "bmi": "25.6",
    "bp": "122/79 mmHg",
    "hr": "81 bpm",
    "smoking": "Current smoker (38 pack-yr)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "27 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment prompted by a prior prostate cancer diagnosis and a recent PSA rise to 19.0 ng/mL."
    },
    {
      "s": "History",
      "t": "A 73-year-old active dairy farmer living with his partner (unmarried), this gentleman first entered clinical evaluation in 2022 for an elevated PSA and subsequently received a Gleason 4+3 diagnosis on an earlier biopsy. He endures severe lower urinary tract symptoms, scoring 33 on the IPSS, which heavily disrupts his daily farm duties. His background includes hypercholesterolaemia treated with simvastatin and rosuvastatin, chronic kidney disease with an eGFR currently under 60, and osteoarthritis managed via paracetamol PRN. He stays physically active, cycling roughly 30 kilometres three times weekly, and is a current smoker (38 pack-yr). Outside of urological matters, he maintains routine podiatry visits and completed a stable cardiology check in autumn 2024. The commute to this clinic exceeds one hour by train, and he is escorted by his sister, who holds next-of-kin status."
    },
    {
      "s": "Physical examination",
      "t": "DRE: A firm, discrete nodule is palpable within the right posterior peripheral zone, while the rest of the gland presents as symmetrically enlarged and smooth. General inspection shows a well-nourished individual in no acute distress. Lung fields are clear, and cardiac rhythm remains regular at 81 beats per minute. Blood pressure registers at 122/79 mmHg, with bilateral peripheral pulses intact."
    }
  ],
  "occupation": "active dairy farmer",
  "marital": "Living with partner (unmarried)",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)",
    "Podiatry — routine foot care"
  ],
  "alcohol": "1 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 33/35 (severe LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Catharina Ziekenhuis (Eindhoven)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_afbc5ebc0d4e
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.29 ng/mL²
  - PSA velocity: 4.32 ng/mL/yr
  - Prior PSA: 14.6 ng/mL
  - Prostate volume: 65.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7148355 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis
  - Current medication: simvastatin, rosuvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 4. PSAD 0.29. Prostate volume 65 mL. DRE nodus. csPCa 0.71.

Vitals: weight 84 kg, height 181 cm, BMI 25.6, BP 122/79 mmHg, HR 81 bpm. Smoking: Current smoker (38 pack-yr).

Chief complaint: Clinical reassessment prompted by a prior prostate cancer diagnosis and a recent PSA rise to 19.0 ng/mL.

History: A 73-year-old active dairy farmer living with his partner (unmarried), this gentleman first entered clinical evaluation in 2022 for an elevated PSA and subsequently received a Gleason 4+3 diagnosis on an earlier biopsy. He endures severe lower urinary tract symptoms, scoring 33 on the IPSS, which heavily disrupts his daily farm duties. His background includes hypercholesterolaemia treated with simvastatin and rosuvastatin, chronic kidney disease with an eGFR currently under 60, and osteoarthritis managed via paracetamol PRN. He stays physically active, cycling roughly 30 kilometres three times weekly, and is a current smoker (38 pack-yr). Outside of urological matters, he maintains routine podiatry visits and completed a stable cardiology check in autumn 2024. The commute to this clinic exceeds one hour by train, and he is escorted by his sister, who holds next-of-kin status.

Physical examination: DRE: A firm, discrete nodule is palpable within the right posterior peripheral zone, while the rest of the gland presents as symmetrically enlarged and smooth. General inspection shows a well-nourished individual in no acute distress. Lung fields are clear, and cardiac rhythm remains regular at 81 beats per minute. Blood pressure registers at 122/79 mmHg, with bilateral peripheral pulses intact.

Patient info: active dairy farmer; Living with partner (unmarried); Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 1 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 33/35 (severe LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Podiatry — routine foot care.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.37-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.40: PI-RADS 4, PSA 13.2, PSAD 0.14, age 66, DRE Nodus -> BIOPSY (uncertain). He wrote: "There is no information on ISUP in the earlier cancer diagnosis and missing also size of earlier PIRADS 4 lesion"
  2. distance 2.00: PI-RADS 4, PSA 7.8, PSAD 0.165, age 74, DRE Normal -> BIOPSY (clear). He wrote: "Active surveillance of unfavorable intermediate risk disease, no previous re-biopsy. Likely biopsied index lesion on MRI, but note small tumor extension on biopsy (4mm)…"
  3. distance 2.24: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy is mandated when there is a lesion on MRI that mandates it to confirm histological progression before a change in treatment strategy. It also states that targeted and perilesional biopsy cores should be taken if a PI-RADS $\ge 3$ lesion is present.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of biopsy is not decisive because the guideline makes the decision based on the presence of a lesion on MRI mandating confirmation, which is not explicitly established here. Expert-Cohort's finding that the prior positive biopsy means the panel does not determine the decision is correct, as the guideline focuses on documented grade and surveillance history, which are not yet established.

WHAT WE STILL NEED
The guideline requires information on the documented grade of the prior biopsy and the number and dates of biopsy sessions.
The prior biopsy status is documented as "Positive" on the panel, and the specific Gleason or ISUP grade is not provided in the available information.
The number and dates of prior biopsy sessions are not provided in the available information.
Whether the patient is on a surveillance protocol with a confirmatory biopsy due is not provided in the available information.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on establishing the documented grade and history of the prior prostate biopsy to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> Is the patient on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What is the free-PSA fraction?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior prostate biopsy?
  Q2. What is the number and dates of prior biopsy sessions?
  Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
WHAT IS THE LESION SIZE AND ZONE OF THE mpMRI? The mpMRI report states: "a discrete, intensely hypointense focus within the right posterior peripheral zone at mid-gland, occupying roughly 12 x 8 x 10 mm."
psa_trend
WHAT IS THE SERIAL PSA TREND (rising, flat, or falling)? The serial PSA trend shows values: "Aug 2022: 2.5", "Nov 2023: 6.9", "Jan 2025: 19.0". This is a rising trend.
previous_notes
IS THE PATIENT ON A SURVEILLANCE PROTOCOL WITH A CONFIRMATORY BIOPSY DUE? The previous notes state: "Catharina Ziekenhuis conducted a multiparametric MRI that yielded a PI-RADS 4 result. With the earlier biopsy confirming Gleason 4+3 disease alongside these new imaging markers, a referral to the urology outpatient clinic was processed for further clinical assessment." This does not explicitly state a surveillance protocol with a confirmatory biopsy due.
laboratory_results
WHAT IS THE FREE-PSA FRACTION? The laboratory results show: "Free PSA: 1.94 ng/mL" and "%Free PSA: 10%".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes mentioned the prior biopsy result which is more relevant to the current decision than a general family history.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 4 lesion located in the right mid peripheral zone.
PSA velocity is high, with a trend showing a rise from 6.9 ng/mL in Nov 2023 to 19.0 ng/mL in Jan 2025.
DRE finding is a "Nodus" (nodule).
AGAINST sampling this patient now
Prior biopsy was positive, meaning a tissue diagnosis already exists.
The decision hinges on the documented grade of the prior biopsy, which is not yet established.

WHERE THIS LEANS
The findings suggest a need to establish the prior biopsy grade to guide the next step, which aligns with the EAU guideline's requirement for this information.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 19.00 ng/mL over 3 points spanning 29 months; velocity +6.79 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 32.4 ng/mL, conformal 95% band 9.3-112.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.09 epistemic (95% band 0.40-0.75), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.57  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)

  documented prior grade in the opened documents: GG 3 ("Gleason 4+3")

RULE THAT FIRED: documented prior grade GG 3 (Gleason 4+3) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—did not fully answer the moderator's questions. Specifically, the documented Gleason or ISUP grade of the prior biopsy (Q1), the number and dates of prior biopsy sessions (Q2), and whether the patient is on a surveillance protocol with a confirmatory biopsy due (Q3) were not explicitly stated in the retrieved information.

ALIGNMENT WITH THE PANEL
The retrieved evidence does not directly overturn the PANEL-PROTOCOL's answer of "NO BIOPSY," which was based on the finding "documented prior grade GG 3 (Gleason 4+3)." The retrieved notes only state that the earlier biopsy confirmed Gleason 4+3 disease, which supports the panel's conclusion that a documented grade of GG 3 dictates deferral.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior prostate biopsy? Not answered by retrieved documents.
Q2. What is the number and dates of prior biopsy sessions? Not answered by retrieved documents.
Q3. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Not answered by retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The documented prior grade (GG 3) carries the most weight as it is the explicit rule that fired in the PANEL-PROTOCOL, indicating that the established pathological diagnosis dictates the management pathway. The PSA trend and PI-RADS 4 lesion are secondary, as the panel protocol suggests these do not override the established grade.

MY SUGGESTION TO THE CHAIR
The record is not ready for a final decision because the critical information required by the EAU guideline—the documented grade and surveillance status—remains unretrieved. The decision cannot be made until the registrar provides answers to Q1, Q2, and Q3.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The panel protocol concluded no biopsy is needed based on the documented prior grade of GG 3, which dictates management. While the PSA trend was rising, the critical information regarding the documented grade and surveillance status remained unretrieved, leading the Verifier to suggest deferral. The evidence converged on deferral because the established pathological diagnosis, GG 3, was the decisive factor overriding the uncertainty from the expert bids.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
